drug costs

Before COVID, hepatitis C held the distinction of claiming more American lives each year than any other infectious disease — that’s despite the marketing of several relatively affordable, highly effective treatments.

Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices have not delivered on those savings.

The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?

With a decision expected this fall on whether Florida can import cost-saving drugs, the state lashed out after federal officials raised issues such as a requirement for a secured warehouse in Michigan.

The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drug-makers are fighting the negotiations with lawsuits.

Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development nor their therapeutic value, research shows.

A new report by AARP found that the top 25 drugs — covered under Medicare Part D — have almost tripled in price since they first entered the market.

The state alleges the federal agency violated the Freedom of Information Act. The revised lawsuit includes allegations that the FDA did not properly respond to a records request submitted in May.

Medicare soon will start something it hasn't done in its 58-year history: negotiate on drug prices. On Sept. 1, Medicare will target the first 10 drugs for price negotiations.

At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients. Here's what the fuss is all about.